Role of Dendritic Cells in Immune Dysfunction by Savary, Cherylyn A.
TEXAS MEDICAL CENTER NASA/JOHNSON SPACE CENTER
COOPERATIVE AGREEMENT PROGRAM NCC 9-36, ROUND II
COVER SHEET FOR FINAL REPORT
Please follow this format:
Name of Subcontractor:
Title:
Institution:
Cherylyn A. Savary, Ph.D.
Assistant Professor
University of Texas M.D.
Name of Project: Role of Dendritic
Amount of Grant:
* Amount Spent, if Different from Amount Granted:
Date ProjectWas Completed: June 30, 1998
Anderson Cancer Center
Cells in Immune Dysfunction
Grants Officer: Donna S. Gilberg, CPA
Title: Manager, Sponsored Programs
Phone: (713)794-1825
Fax: (713)796-0381
https://ntrs.nasa.gov/search.jsp?R=19990025374 2020-06-15T22:26:17+00:00Z
Principal Investigator: Cherylyn A. Savary, Pit D.
TEXAS MEDICAL CENTER NASA/JOHNSON SPACE CENTER
COOPERATIVE AGREEMENT NCC 9-36
Applications Subcontract Program, Round 2
Final Report
Name of Institution:
Name of Subcontractor:
Title of Project:
University of Texas M.D. Anderson Cancer Center
University of Texas M.D. Anderson Cancer Center
Role of Dendritic Ceils in Immune Dysfunction (Savary)
Specific Aims:
1. Application of the NASA bioreactor to enhance
.
,
cytokine-regulated proliferation and
maturation of dendritic cells (DC).
Compare the frequency and function of DC in normal donors and immunoeompromised
cancer patients.
Analyze the effectiveness of cytokine therapy and DC-assisted immunotherapy (using
bioreactor-expanded DC) in a murine model of experimental fungal disease.
Studies and Results:
Our investigations have provided new insight into DC immunobiology and have led to the
development of methodology to evaluate DC in blood of normal donors and patients (1,2).
Information gained from these studies has broadened our understanding of possible mechanisms
involved in the immune dysfunction of space travelers and earth-bound cancer patients, and
could contribute to the design of novel therapies to restore/preserve immunity in these
individuals. Several new avenues of investigation were also revealed, one of which has been
awarded funding through NRA-96-OLMSA-03. The results of studies completed during Round
2 are summarized below. Additional details are provided in the manuscripts and abstracts cited
in the references and included in the Appendix.
AIM L Application of the NASA bioreactor to enhance eytoMne-regulated proliferation and
maturation of DC. In Round 1 we showed that the 3D environment of the NASA bioreactors
(including the HARV, STLV and RCCS-D vessels) supported the generation and maturation of
human DC from CD34 + progenitors. Bioreactor-generated DC (3D-DC), however, displayed
several differences compared to DC generated in standard 2D culture conditions (2D-DC), i.e.,
the proliferative and phagocytic activity of 3D-DC was reduced compared to 2D-DC. The 3D-
DC though, displayed higher allostimulatory activity and higher levels of heat shock proteins
(Hsp). According to current models, DC maturation progresses from a less mature stage,
characterized by high antigen uptake/processing capabilities and low antigen-presenting function,
to a more mature stage in which antigen uptake/processing capabilities are lost as antigen-
presenting functions are upregulated. Based on this model, our results suggest that DC
maturation may be enhanced in the NASA bioreactors. These data were presented at the annual
meeting of the Biotechnology Cell Science Program Investigators Working Group (1997), and as
a poster at the 13 th Annual Meeting of the American Society for Gravitational and Space Biology
(3).
During Round 2, we further analyzed the characteristics of human 3D-DC versus 2D-DC,
and continued to explore ways to enhance DC generation in NASA bioreactors. During our
studies, considerable interest arose in FLT3-1igand - a cytokine that substantially enhances DC
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generation in vivo in mice, and that appears to
have potential clinical application. It is known
that FLT3L has little activity on its own, but can
enhance the activity of other DC-promoting
cytokines. We analyzed the effect of this agent
on DC generation/maturation in the bioreactor.
In agreement with our findings in Round 1, 3D-
DC generated in the presence of a basic DC
cytokine cocktail (GM-CSF+TNF{x+stem cell
factor [SCF]) displayed higher allostimulatory
activity than 2D-DC (Fig. 1). Addition of
FLT3L to this cocktail had a slight enhancing
effect on the stimulatory activity of DC obtained
from either culture condition. Using flow
cytometry we found that, in comparison to 2D-
DC, a higher proportion of 3D-DC generated
with or without FLT3L, displayed CD86
eostimulatory molecules (a mark of more
mature/activated DC) (Fig. 2). FLT3L enhanced
the proportion of CD86 + in 2D cultures (Fig.
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Pig. 1. Effect of FLT3L on the ailostimulatory activity of DC.
DC were generated from CD34 + progenitors in standard 2D
cultur_ or in NASA bioreaetors OD). Cultures were
supplemented with GM-CSF, TNFct and SCF, with or without
FLT3L. Proliferation was measured in a standard mixed
lymphocyte reaction using 3HTdR incorporation.
Stimulator:responder ratio = 1:20.
2b), but by far, the highest proportion of CD86 + DC was generated in 3D cultures supplemented
with FLT3L (Fig. 2d). These results suggest that FLT3L promotes generation of more mature
DC - a process which is further enhanced in the 3D environment of the bioreactors.
Another consistent finding in our investigations, was that the intensity of HLA-DR (MHC
Class II) expression was reduced on 3D-DC regardless of the eytokine cocktail used to generate
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Fig. 2. Effect of FLT3L on expression ofCD86 byDC. DC were generated from
CD34 ÷ progenitors in standard 2D cultures (a and b) or in 3D NASA bioreactors (c
and d). Cultures were supplemented with GM-CSF, TNFct and SCF alone (a and
e), or together with FL'I3L (b and d). Values rtpresent ptwe_tage ofCD86 ÷ cells.
these cells (Table 1). This
observation (in the 3D cultures only)
runs counter to the general model of
DC maturation in which HLA-DR is
increased upon maturation. It is
important to note, though, that this
model is based primarily on results
from 2D culture conditions. It is
possible that HLA-DR expression
Table 1. Reduced expression of HLA-DR by
DC generated in NASA bioreactors.
Donor #
Density of I_...A-DR (MFI) a
2D-I)C 3D-DC
1 1279 207
2 247 105
3 756 280
4 1910 1229
5 202 134
aValues represent mean fluorescence intensity
(MFI) of I-ILA-D1L MFI is a measure of antigen
density.
2
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differs when DC are grown in 3D, or that some stress associated with simulated microgravity
alters the assembly or transport of HLA-DR molecules.
HLA-DR plays a central role in antigen presentation to CD4 + helper T cells. Lower
expression of HLA-DR on antigen presenting cells could result in reduced stimulation of CD4 + T
cells, and consequently, a blunted immune response. Interestingly, Hsp have been shown to bind
to HLA-DR subunits as the MHC Class II molecule is assembled in the cytoplasm. An intriguing
possibility is that the Hsp induced in DC cultured in the bioreactor (3), might sequester HLA-DR
within the cytoplasm and prevent transport of these molecules to the cell surface. Upregulation
of stress proteins might reflect a protective response of DC against as yet under'reed stressors,
some of which might resemble those experienced in microgravity. Thus, understanding the role
of Hsp in DC maturation might provide new insight into the molecular pathways that are
disturbed in disease or in space. Some of these questions will be addressed as part of the NRA-
96-OLMSA-03 grant. A manuscript describing the results of our studies of DC generation in the
NASA bioreactor is currently in preparation.
AIM 2. Compare the frequency and function of DC in normal donors and immunocompromised
cancer patients. Patients recovering from stem cell transplantation are immunoeompromised and
thus at high risk of infection. We hypothesized that
2.0 a deficiency in DC might be an underlying cause of
the lymphopenia experienced by these patients,
1.5 since antigen presenting cells are required for the
optimum activation and proliferation of T
lymphocytes. In Round 1, we developed a
1.0 multidimensional flow eytometrie test to analyze
DC in peripheral blood (1). We found that breast
•_ cancer patients (all undergoing some form of
,_ 0.5 chemotherapy), and patients who were 2-6 months
post stem cell transplantation, displayed a
0 significantly lower proportion of circulating DC
Pre Post compared to normal donors (1). In Round 2, we
extended this analysis to a group of sarcoma
Fig. 3. Effect of chemotherapy on circulating DC. patients before and after chemo-immunotherapy.
The percentage of DC (i.e. lineage negative, HLA-
DR+cells) in blood of cancer patients was tested We found that these patients displayed normal, or
prior to (Pre) and after (Post) high dose chemotherapy + above normal, levels of circulating DC prior to
immunotherapyusing a multidimensionalflow therapy, but that these leukoeytes were severely
eytometrie technique (1,2). Shaded area represents
range of circulating DC in normal donors. Lines decreased aider a combination of
represent 7 different patients, chemotherapy+immunotherapy (Fig. 3). As is often
the case in clinical studies, it was not possible to test the effects of chemotherapy or
immunotherapy alone. However, the combined results from breast cancer patients (1) and
sarcoma patients, suggest that any treatment which includes chemotherapy, can severely suppress
DC. This could explain the lymphopenia and high susceptibility of these patients to infections
(particularly fungal infections).
Interestingly, we found that functional DC could be generated from CD34 ÷ progenitors
obtained fi'om the patients described above. Figure 4 shows that these DC had potent
allostimulatory activity. Such observations are important, since in vitro generated DC might
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Fig. 4. Generation of allostimulatory DC from CD34
progenitors of cancer patients. DC were generated from
blood of sarcoma patients and normal donors, and tested
for the ability to stimulate proliferation of allogeneie T
cells in a standard mixed lymphocyte reaction as
described in Fig. 1.
eventually be reinfused to potentiate the immunity
of patients post-therapy. Alternatively, antigen-
stimulated DC could be used to stimulate
autologous T cells in vitro for use in adoptive
therapy.
We believe that such an approach might be
used to enhance the immunity of bone marrow
transplanted patients against fungi. To test this,
we In'st investigated whether DC from normal
donors could present fungal antigens to
autologous T lymphocytes. It is now known that
DC can be generated either from CD34
progenitors (DC34) as described above, or from
CD14 ÷
monocytes (DCMo) cultured for several days with
GM-CSF+ ]I,-4. We tested both types of DC for
their ability to present fungal antigens to autologous T lymphocytes. As seen in Fig. 5, both
populations were effective in stimulating proliferation of autologous T lymphocytes to
Aspergillusfumigatus. Stimulation was also observed for Candida albicans (data not shown).
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Fig 5. IX2presentation of A, fumtgatua antigens to autologousT lymphoeytes.
IX3were generatedfromCD34÷progenitors (DC_) or from monoeytes 03Cu,,)
of normal donors,irradiated, culturedwithheat-killedA. fumigatus conidta, and
tested for the ability to stimulateproliferation of autologousT lymphoeytes.
Typical monocytes (Mo) were also tested asantigen presentingcells to illustrate
the efficiency of DC. Bars representa stimulationindex(Sir)whereSI=cpm of
antigen-stimulated lymphoeytes/cpm oftmsfimulatedlymphocytes.
More importantly, we next showed that in 3 of 4 stem cell transplanted patients tested,
donor DC34 generated from blood collected pre-transplant, could potentiate the proliferative
response of autologous post-transplant lymphocytes against A. fumigatus (Fig. 6). These results
have important clinical implications, since there is presently no effective treatment for
aspergillosis in severely immunoeompromised patients. These data were presented at the annual
4
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Fig 6. DC-mediated augmentation of antifungal response post stem cell transplantation.
DC were generated fi'om CD34 +progenitors collected pra-transplantation, and tested for
the ability to stimulate proliferation of post-transplant autologous T lymphocytes to A.
furntgatus.
meeting of the Biotechnology Cell Science Program Investigators Working Group (1998), and as
a poster at the Keystone Symposia Conference on Cellular and Molecular Biology of Dendritic
Cells (4). A manuscript describing these results is near completion.
AIM 3. Analyze the effectiveness of cytokine therapy and DC-assisted immunotherapy (using
bioreactor-expanded DC) in a murine model of experimental fungal disease. In Round 1 we
observed some differences in DC generated from bone marrow of mice in 2D versus 3D
conditions. Specifically, a higher proportion ofNLDC-145 ÷ cells (a surface marker expressed by
murine DC) was detected in 3D bioreactor cultures. It was our intention to compare the ability of
2D-DC and 3D-DC to protect mice from infection with Aspergillus or Candida. Unfortunately,
our mouse colony at M.D. Anderson became infected with pinworms when we had completed
only initial studies to determine the lethal dose of fungi in our C57BL/6 strain. These
circumstances prevented us from continuing our in vivo tests. However, we continued to study
murine DC through collaboration with Dr. Jagan Sastry at the M.D. Anderson facilities in
Bastrop, TX.
We analyzed DC in murine lymph node tissues cultured by Dr. Sastry in standard 2D
cultures (T flasks) and in the bioreactor. In contrast to the increased levels of marrow-derived
DC observed in our own bioreactor studies, we found that DC from lymph nodes were often
reduced in 3D cultures (see final report of Dr. J. Sastry). The observed differences could indicate
differences in the degree of differentiation of these two DC subsets. According to current
models, DC generated from marrow precursors, circulate in the blood and migrate into peripheral
tissues. After encounter with antigen, the DC undergo maturation that allows them to migrate to
areas of lymphocyte accumulation (e.g. lymph nodes) where they can interact with a large
number of T lymphocytes, including antigen specific CTL. This maturation is believed to be
terminal, and the DC may be destroyed upon interaction with the CTL. Murine marrow contains
DC progenitors that are not likely to encounter antigen during culture. Therefore, it is expected
that they may be longer-lived than the lymph node DC. This could explain the increased levels
of DC observed in our own experiments. Lymph node DC, on the other hand, may be more
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mature, may encounter CTL, and thus may be short-lived. It is possible that continued
supplementation of CTL cultures with autologous DC could sustain or promote lymphocyte
proliferation and function. It must also be considered that marrow and lymph node DC might be
derived from different lineages of cells (e.g. myeloid vs lymphoid), that display different culture
requirements or growth kinetics. The results of these studies are in a manuscript in preparation
(5).
Significance. DC are considered to be the most potent of antigen presenting cells. Only recently
though, has it been possible to expand this rare leukocyte subset in vitro in eytokine-
supplemented cultures. To our knowledge, our studies are the first of their kind to generate and
cultivate DC in a 3D environment. In Round 2, we have continued to improve this culturing
environment by addition of FLT3L to our cocktail of growth factors. A long-term goal is to
generate sufficient numbers of fully differentiated DC for in vivo supplementation/restoration of
patients who we observed have low numbers of circulating DC. In Round 2 we showed that this
may indeed be possible, since DC could potentiate the in vitro antifungal response of severely
immunoeompromised patients. Our data suggest that the bioreactor might represent a novel tool
with potential clinical application, for generating fully mature DC.
We believe that the NASA bioreactor will continue to provide us with a unique
opportunity to analyze in depth the cellular and molecular events associated with DC maturation
from its earliest progenitor to terminal differentiation, as this entire process appears to be
accomplished in the bioreactor. A clear understanding of DC immunobiology will be important
to understanding the mechanism of DC dysregulation in cancer patients - information that might
also give us clues about the mechanism of the blunting of immunity associated with spaceflight.
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Funding resulting from these studies:
NRA-96-OLMSA-03 "Use of NASA Bioreactors in a Novel Scheme for Immunization Against Cancer"
PI: C.A. Savary, Ph.D.; FY 1997 to FY 2000; $465,000
Other activities/accomplishments during Round 2:
Feb. 1998 - presented results of the present studies at the annual meeting of the Bioteelmology Cell Science Program
Investigators Working Group.
Student involvement in these studies -
Monica Crrazziutti, M.D., Clinical Fellow
Luis Tome, M.D., Clinical Fellow
Alysson Ford, summer student, King Foundation Summer Research Program
Lee Aleksich, summer student, NASA Sharp Plus/Qem Program
Manu Goyal, summer student; NASA Sharp Plus/Qem Program
absWaet of project accepted for presentation at the AJAS/AAAS conference (Appendix 3)
